Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: An in situ and ex vivo study

British Journal of Dermatology

Volumn 166, Issue 2, 2012, Pages 298-305

  Van Der Zee, H H ^a   Laman, J D ^a   De Ruiter, L ^a   Dik, W A ^a   Prens, E P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CXCL9 CHEMOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; RANTES; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PUNCH BIOPSY; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; SKIN INFLAMMATION; SUPPURATIVE HIDRADENITIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELLS, CULTURED; CYTOKINES; DERMATITIS; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; SKIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856207980     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10698.x     Document Type: Article

References (21)

1. Jemec GB, Heidenheim M, Nielsen NH,. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35: 191-4.
2. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596-601.
3. Jemec GB, Heidenheim M, Nielsen NH,. Hidradenitis suppurativa- characteristics and consequences. Clin Exp Dermatol 1996; 21: 419-23.
4. Alikhan A, Lynch PJ, Eisen DB,. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60: 539-61.
5. van der Zee HH, van der Woude CJ, Florencia EF, et al. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol 2010; 162: 195-7.
6. Matusiak L, Bieniek A, Szepietowski JC,. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol (Stockh) 2009; 89: 601-3.
7. van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164: 1292-8.
8. Mekkes JR, Bos JD,. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158: 370-4.
9. Lee RA, Dommasch E, Treat J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2009; 60: 565-73.
10. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-17.
11. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008; 158: 567-72.
12. Adams DR, Yankura JA, Fogelberg AC, et al. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 2010; 146: 501-4.
13. Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol 2011; 165: 391-8.
14. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-79.
15. Yazdanyar S, Jemec GB,. Hidradenitis suppurativa: a review of cause and treatment. Curr Opin Infect Dis 2011; 24: 118-23.
16. Fantuzzi F, Del Giglio M, Gisondi P, et al. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets 2008; 12: 1085-96.
17. Hurley H,. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Dermatologic Surgery: Principles and Practice (, Roenigk RK, Roenigk HH Jr, eds). New York: Marcel Dekker, 1989; 729-39.
18. Companjen AR, van der Wel LI, Wei L, et al. A modified ex vivo skin organ culture system for functional studies. Arch Dermatol Res 2001; 293: 184-90.
19. Wolk K, Warszawska K, Hoeflich C, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 2011; 186: 1228-39.
20. Gulliver WP, Jemec GB, Baker KA,. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2011 [Epub ahead of print. DOI ].
21. Marble DJ, Gordon KB, Nickoloff BJ,. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci 2007; 48: 87-101.